EN DE
Watch Sinew Pharma Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sinew Pharma Inc. (6634) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Sinew Pharma Inc. stock TWD 14.60, price TWD 56.70, that is 74.3% below the price, quality 43 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0006634009

SP Sinew Pharma Inc. logo Thin data Nov 8, 2026

Sinew Pharma Inc.

6634 · TWO
Weakest Setup

Our calculation puts a fair price 74% below what the stock costs today.

Quality 43/100
Mixed vs. peers (3/6)
Fair value 14.60 TWD · Strongly overvalued
Weak Growth (revenue 5y −36.7 %/yr in TWD)
Negative free cash flow
Narrow moat 8/100 · thin data
Thin data
Watch Sinew Pharma Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

79.90 TWD 30.10 TWD Fair Value 14.60 TWD Dec 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

11‑month range 30.10 TWD – 79.90 TWD · fair‑value band 9.64 TWD – 18.25 TWD · the 56.70 TWD price screens above the 14.60 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Sinew Pharma in your weekly email

Every Wednesday you see whether Sinew Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases.

Show moreShow less

The company's products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan.

It is also developing SNP-810 is in phase II clinical trial for use in pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for acetaminophen poisoning, and SNP-830 and SNP-840, which in pre-clinical trial are used as hepatotoxicity-free analgesic medicines in the United States.

Sinew Pharma Inc. was founded in 2014 and is based in Taipei City, Taiwan.

Stock analysis

Sinew Pharma Inc. (6634) currently trades at 56.70 TWD, while our model-based Fair Value estimate is 14.60 TWD, 74% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 9.64 TWD (bear) to 18.25 TWD (bull), the price of 56.70 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Sinew Pharma Inc. reported revenue of 47.0K TWD in FY2025 versus 6.2M TWD in FY2021, a compound −70.5%/yr. Reported net income was −124M TWD in FY2025.

Key figures

Market cap 4.0B TWD (≈ $123M) Micro · EPS (TTM) −1.66 TWD · Return on equity −10.9% · Return on assets (EBIT) −11.2% (5-year average) · Operating margin −283,143% · Revenue (TTM) 47.0K TWD · Free cash flow −97.2M TWD · Net cash 38.6M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 29% below its 52-week high and 88% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −74%, 6634 screens richer than that median.

Fair Value models

Bear 9.64 TWD Fair Value 14.60 TWD Bull 18.25 TWD
Price 56.70 TWD · Downside -74.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 9.64 TWD 14.60 TWD 18.25 TWD 52
All 1 models by family
Asset-Based
NCAV (Graham) 9.64 TWD 14.60 TWD 18.25 TWD 52

Open the full fair value analysis →

Quality Score breakdown

Overall quality 43/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 57
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 77
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 48
How calm the share price moves, does not count
Price momentum 49
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 66
Distance to the 52-week high, does not count
New shares 77
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−47.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.7%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−18,204.8% (2020) → −298,140.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6634 screens overvalued: fair value 74% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Sinew Pharma Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 43 · Below median
Fair Value upside −73.7% · Bottom 25%
Profitability
Return on assets −11.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 3.63× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 6634
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 6634
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 6634
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 6634
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 6634
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 6634
argenx SE ARGX $927.21 $908.40 −2% vs 6634
CSL Limited CSL A$200.77 A$183.04 −9% vs 6634
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 6634
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 6634

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sinew Pharma Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sinew Pharma Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6634

Frequently asked questions

Is Sinew Pharma Inc. (6634) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 14.60 TWD versus a price of 56.70 TWD, about 74% lower (overvalued).
What is the fair value of 6634?
Our model-based fair value for Sinew Pharma Inc. is 14.60 TWD (as of Nov 8, 2026), built from audited fundamentals. The current price: 56.70 TWD.
What is the quality score of 6634?
Sinew Pharma Inc. has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sinew Pharma Inc. (6634)?
Our model-based price target is the fair value of 14.60 TWD (as of Nov 8, 2026) from 1 valuation models. Cautious scenario 9.64 TWD, optimistic scenario 18.25 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Sinew Pharma Inc. stock forecast for 2026?
Our models put fair value at 14.60 TWD, about 74% lower versus a price of 56.70 TWD (overvalued). Cautious scenario 9.64 TWD, optimistic scenario 18.25 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Sinew Pharma Inc. (6634)?
Sinew Pharma Inc. reported trailing-twelve-month revenue of about 47.0K TWD (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Sinew Pharma Inc. (6634)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sinew Pharma Inc. it is 14.60 TWD per share (as of Nov 8, 2026), against a price of 56.70 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Sinew Pharma Inc. stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 6634 trades above its calculated fair value: price 56.70 TWD, fair value 14.60 TWD, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6634?
No. The price is what the market pays today (56.70 TWD); the fair value is what the company's own numbers justify (14.60 TWD). For Sinew Pharma Inc. the two are 42.10 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Sinew Pharma Inc. worth?
The market values Sinew Pharma Inc. at about 4.0B TWD (market capitalisation, as of Nov 8, 2026). Per share that is 56.70 TWD; our models calculate a fair value of 14.60 TWD per share.
What do the bullish and bearish scenarios say about 6634?
Our models span a range for Sinew Pharma Inc.: cautious scenario 9.64 TWD, base 14.60 TWD, optimistic 18.25 TWD per share (as of Nov 8, 2026, price 56.70 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sinew Pharma Inc. (6634)?
Balance-sheet figures for Sinew Pharma Inc. (as of Nov 8, 2026): return on equity −10.9%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 6634 from its 52-week high?
Sinew Pharma Inc. trades at 56.70 TWD, about 29% below its 52-week high of 79.90 TWD and 88% above the low of 30.10 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 14.60 TWD is for.
Which stocks are comparable to Sinew Pharma Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sinew Pharma Inc. stock attractive at the current price?
The data as of Nov 8, 2026: price 56.70 TWD, calculated fair value 14.60 TWD (−74%), Quality Score 43/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6634 calculated?
We run Sinew Pharma Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 14.60 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Sinew Pharma Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sinew Pharma Inc. (6634)?
The closing price on Nov 9, 2026 was 56.70 TWD. Our model-based fair value is 14.60 TWD, about 74% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sinew Pharma Inc. right now?
The price sits above even our optimistic bull case (18.25 TWD). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (9.64 TWD to 18.25 TWD) leaves room in how you read the outcome.

Key figures of Sinew Pharma Inc.

How large is the market capitalisation of Sinew Pharma Inc. (6634)?
The market capitalisation of Sinew Pharma Inc. is 4.0B TWD (≈ $123M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Sinew Pharma Inc. (6634)?
Earnings per share at Sinew Pharma Inc. are −1.66 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Sinew Pharma Inc. (6634)?
The return on equity (ROE) of Sinew Pharma Inc. is −10.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sinew Pharma Inc. (6634)?
On an EBIT basis the return on assets of Sinew Pharma Inc. is −11.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sinew Pharma Inc. (6634)?
The operating margin of Sinew Pharma Inc. is −283,143% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Sinew Pharma Inc. (6634) generate?
The free cash flow of Sinew Pharma Inc. is −97.2M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sinew Pharma Inc. (6634) hold?
Sinew Pharma Inc. holds more cash than debt, 38.6M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Sinew Pharma Inc. in the live analysis

One click puts Sinew Pharma Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.